. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Dig Dis Sci. 2019 Apr 3;64(7):2031–2038. doi: 10.1007/s10620-019-05595-6

Table 2.

Descriptive data

	Overall (n = 149)	1 or 2 HBV revaccination doses administered (n = 87)	3 HBV revaccination doses administered (n = 62)	p value
Seroconversion to HBsAb > 10 IU/L
All ages, %	49.7	40.2	62.9	< 0.01
Age < 40 years, %⁺	63.6	52.9	81	< 0.04
Age ≥ 40 years, %⁺	41.5	32.1	53.7	< 0.04
Mean follow-up HBsAb titer
All ages, IU/L (SD)	162.5 (299.8)	93.3 (200.0)	259.6 (379.0)	< 0.001
Age < 40 years, IU/L (SD)⁺	285.1 (391.5)	172.0 (283.5)	468.3 (465.8)	< 0.01
Age ≥ 40 years, IU/L (SD)⁺	91.7 (197.7)	42.8 (87.1)	152.7 (269.1)	< 0.01

⁺

Performed as part of secondary analysis

HBV hepatitis B virus, HBsAb hepatitis B surface antibody, IU/L international units/liter, SD standard deviation